Business Context and Reporting Period
Company: Omeros Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: October 4, 2018
Reporting Period: Specific event date of October 4, 2018
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a procedural report regarding regulatory filings.
Material Changes
No material financial changes or operational updates were reported. The filing documents a routine administrative event: the receipt of an order from the U.S. Securities and Exchange Commission (SEC) extending a prior grant of confidential treatment.
Guidance, Outlook, and Risks
- Event Details: The SEC order extends confidential treatment for certain information contained in two exhibits originally filed during the Company's 2009 initial public offering.
- History: Confidential treatment was originally granted on October 7, 2009, and previously extended in orders dated September 16, 2012, and September 3, 2015.
- Exhibits: The filing incorporates by reference an Exclusive License and Sponsored Research Agreement with the Medical Research Council (dated October 31, 2005) and an amendment to that agreement (dated May 8, 2007).
- Outlook: No forward-looking guidance or management commentary regarding future financial performance is provided in this document.
Investor Verification Checklist
- Verify the specific content of the exhibits (10.1 and 10.2) referenced in the 2009 S-1 filing to understand the scope of the confidential information.
- Confirm the expiration date of the newly granted confidential treatment period, as the filing text does not specify the new end date.
- Review the original 2009 IPO documents to contextualize the "Exclusive License and Sponsored Research Agreement" with the Medical Research Council.